Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 04, 2025 10:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic and Sapu Nano Announce DeciparticleTM Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine

AGOURA HILLS, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano today announced new biomarker data identifying a molecular...
November 25, 2025 08:30 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Anticipates Major Fair-Value Uptick Following New Independent JV Valuation

NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands...
November 20, 2025 07:55 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Achieves Breakthrough $1.7 Billion Pipeline Valuation Through GMP Bio Joint Venture

SAN DIEGO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (OTLC) today announces that its joint venture partner, GMP Bio, has completed an independent third-party...
October 31, 2025 08:30 ET | Source: InvestorBrandNetwork (IBN)

NetworkNewsAudio Announces Audio Press Release (APR) on Transforming Once-Marginal Drugs into Category-Changing Assets

AUSTIN, Texas, Oct. 31, 2025 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) title “Nanomedicine Breakthrough Technology Redefining Drug Delivery,...
October 30, 2025 06:00 ET | Source: Oncotelic Therapeutics, Inc.

Sapu Nano to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus)

AGOURA HILLS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a biopharmaceutical company founded to discover, create, test, and deliver transformative...
October 28, 2025 08:30 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Working to Transform Underperforming Compounds into Next-Gen Cancer Therapies

NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of...
October 23, 2025 08:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus)

Accepted Presentations Showcase First-in-Human Development, Manufacturing Innovation, and Predictive Biomarkers for Deciparticle™ Everolimus (Sapu003) AGOURA HILLS, Calif., Oct. 23, 2025 (GLOBE...
October 22, 2025 08:00 ET | Source: InvestorBrandNetwork (IBN)

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Return of Dr. Vuong Trieu, CEO of Oncotelic Therapeutics Inc.

AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce...
October 20, 2025 08:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic to Present at the LD Micro Main Event XIX

AGOURA HILLS, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a biopharmaceutical company founded to discover, create, test, and deliver transformative...
September 22, 2025 08:00 ET | Source: InvestorBrandNetwork (IBN)

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Vuong Trieu, CEO of Oncotelic Therapeutics Inc.

AUSTIN, Texas, Sept. 22, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce...